tradingkey.logo
tradingkey.logo
Suchen

PAVmed Inc

PAVM
Zur Watchlist hinzufügen
6.530USD
+0.040+0.62%
Handelsschluss 05/15, 16:00ETKurse um 15 Minuten verzögert
46.75MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über PAVmed Inc Unternehmen

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

PAVmed Inc Informationen

BörsenkürzelPAVM
Name des UnternehmensPAVmed Inc
IPO-datumJul 27, 2016
CEOAklog (Lishan)
Anzahl der mitarbeiter39
WertpapierartOrdinary Share
GeschäftsjahresendeJul 27
Addresse360 Madison Avenue
StadtNEW YORK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl10017
Telefon12129494319
Websitehttps://pavmed.com/
BörsenkürzelPAVM
IPO-datumJul 27, 2016
CEOAklog (Lishan)

Führungskräfte von PAVmed Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
367.57K
+97.93%
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
21.65K
+64.33%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
21.10K
+66.03%
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
19.34K
+72.04%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Mr. Timothy (Tim) Baxter
Mr. Timothy (Tim) Baxter
Independent Director
Independent Director
--
--
Mr. Shaun M. O'Neil
Mr. Shaun M. O'Neil
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Matt Riley
Mr. Matt Riley
Director of Investor Relations
Director of Investor Relations
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
367.57K
+97.93%
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
21.65K
+64.33%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
21.10K
+66.03%
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
19.34K
+72.04%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Tasso Partners, LLC
12.55%
Scopia Capital Management LP
8.66%
Nagelberg (David S)
7.52%
Kallman (Craig)
5.29%
Aklog (Lishan)
5.05%
Andere
60.92%
Aktionäre
Aktionäre
Anteil
Tasso Partners, LLC
12.55%
Scopia Capital Management LP
8.66%
Nagelberg (David S)
7.52%
Kallman (Craig)
5.29%
Aklog (Lishan)
5.05%
Andere
60.92%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
30.19%
Corporation
12.69%
Hedge Fund
8.68%
Investment Advisor
1.13%
Investment Advisor/Hedge Fund
0.14%
Venture Capital
0.02%
Andere
47.15%

Institutionelle Beteiligung

Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
61
736.95K
10.13%
+659.92K
2025Q4
61
98.91K
9.93%
+37.00K
2025Q3
89
2.39M
8.50%
+565.99K
2025Q2
101
5.16M
29.26%
+2.76M
2025Q1
106
5.16M
31.74%
+3.03M
2024Q4
110
2.41M
17.67%
+156.53K
2024Q3
120
2.58M
24.42%
+197.13K
2024Q2
133
1.94M
20.61%
-301.78K
2024Q1
169
2.19M
26.52%
+433.78K
2023Q4
185
1.60M
20.86%
-48.73K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Tasso Partners, LLC
85.81K
1.36%
+85.81K
--
Feb 21, 2025
Aklog (Lishan)
7.62K
0.12%
--
--
Feb 13, 2026
McGrath (Dennis M)
6.70K
0.11%
+1.00
+0.01%
Feb 13, 2026
O'Neil (Shaun)
5.60K
0.09%
--
--
Feb 13, 2026
Gordon (Michael Adam)
5.00K
0.08%
--
--
Feb 13, 2026
Sargent Investment Group, LLC
33.54K
0.53%
+33.54K
--
Jul 01, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Dec 30, 2025
Merger
30→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Datum
Ex-Dividendentag
Art
Verhältnis
Dec 30, 2025
Merger
30→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
KeyAI